Merck & Co Inc
MRK78.580USD
+0.460+0.59%
Market hours （ET）Quotes delayed by 15 min
197.71BMarket Cap
11.34P/E TTM
More Details of Merck & Co Inc Company
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's segments include Pharmaceutical and Animal Health. Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells its human health vaccines primarily to physicians, wholesalers, distributors and government entities. Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Company Info
Ticker SymbolMRK
Company nameMerck & Co Inc
IPO dateJan 01, 1941
Founded at1970
CEOMr. Robert M. (Rob) Davis
Number of employees75000
Security typeOrdinary Share
Fiscal year-endJan 01
Address126 East Lincoln Avenue
CityRAHWAY
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07065
Phone19087404000
Websitehttps://www.merck.com/
Ticker SymbolMRK
IPO dateJan 01, 1941
Founded at1970
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.21B
46.40%
Vaccines -Gardasil/Gardasil
1.33B
8.54%
Animal Health-Livestock
924.00M
5.95%
Other pharmaceutical
729.00M
4.69%
Animal Health-Companion Animals
664.00M
4.28%
Other
4.68B
30.14%
By RegionUSD
Name
Revenue
Proportion
United States
8.52B
54.88%
Europe, Middle East and Africa
3.45B
22.24%
Latin America
792.00M
5.10%
China
702.00M
4.52%
Other
701.00M
4.51%
Other
1.36B
8.74%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.21B
46.40%
Vaccines -Gardasil/Gardasil
1.33B
8.54%
Animal Health-Livestock
924.00M
5.95%
Other pharmaceutical
729.00M
4.69%
Animal Health-Companion Animals
664.00M
4.28%
Other
4.68B
30.14%
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
4.80%
Wellington Management Company, LLP
3.25%
Geode Capital Management, L.L.C.
2.38%
Other
73.69%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
4.80%
Wellington Management Company, LLP
3.25%
Geode Capital Management, L.L.C.
2.38%
Other
73.69%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.48%
Investment Advisor/Hedge Fund
26.76%
Research Firm
3.49%
Pension Fund
2.53%
Bank and Trust
2.44%
Hedge Fund
1.55%
Sovereign Wealth Fund
1.49%
Insurance Company
0.69%
Family Office
0.11%
Other
19.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
5386
2.02B
80.63%
-18.12M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
251.40M
10.01%
-1.86M
-0.73%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
147.30M
5.87%
+3.91M
+2.73%
Mar 31, 2025
State Street Global Advisors (US)
120.53M
4.8%
-379.67K
-0.31%
Mar 31, 2025
Wellington Management Company, LLP
81.67M
3.25%
+927.62K
+1.15%
Mar 31, 2025
Geode Capital Management, L.L.C.
59.66M
2.38%
-1.52M
-2.49%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
49.23M
1.96%
+29.10M
+144.62%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
34.98M
1.39%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
28.25M
1.13%
-5.33M
-15.86%
Mar 31, 2025
Fisher Investments
24.45M
0.97%
+8.33M
+51.73%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
22.02M
0.88%
+805.58K
+3.80%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
FT Vest DJIA Dogs 10 Target Income ETF
9.97%
First Trust NASDAQ Pharmaceuticals ETF
6.74%
Invesco Dow Jones Industrial Average Dividend ETF
5.13%
Invesco Pharmaceuticals ETF
4.6%
iShares U.S. Pharmaceuticals ETF
4.51%
TBG Dividend Focus ETF
4.42%
VanEck Pharmaceutical ETF
4.31%
ProShares Pet Care ETF
4.3%
Health Care Select Sector SPDR Fund
4.05%
Schwab U.S. Dividend Equity ETF
4.04%
View more
FT Vest DJIA Dogs 10 Target Income ETF
Proportion9.97%
First Trust NASDAQ Pharmaceuticals ETF
Proportion6.74%
Invesco Dow Jones Industrial Average Dividend ETF
Proportion5.13%
Invesco Pharmaceuticals ETF
Proportion4.6%
iShares U.S. Pharmaceuticals ETF
Proportion4.51%
TBG Dividend Focus ETF
Proportion4.42%
VanEck Pharmaceutical ETF
Proportion4.31%
ProShares Pet Care ETF
Proportion4.3%
Health Care Select Sector SPDR Fund
Proportion4.05%
Schwab U.S. Dividend Equity ETF
Proportion4.04%
Dividend
A total of
35.12B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
